Glaukos Corp Stock Price, News & Analysis

Glaukos Corporation (NYSE: GKOS) announces its third quarter 2022 financial results will be released after market close on November 2, 2022. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET) for management to discuss the results. The company focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012. A replay of the call will be available on Glaukos' website post-event.

Glaukos Corporation (NYSE: GKOS) announces its participation in the American Academy of Ophthalmology (AAO) annual meeting, September 30 - October 3, 2022, in Chicago, IL. The company will showcase advancements in glaucoma and corneal health technologies. Key topics include novel intraoperative OCT use, trabecular bypass surgery efficacy, and corneal health presentations. Glaukos will exhibit at booth #4503, highlighting their commitment to innovative ophthalmic treatments. Further details and abstracts are available on the AAO website.

Glaukos Corporation (NYSE: GKOS) announced that both iDose TR Phase 3 pivotal trials achieved their primary efficacy endpoints. The trials showed that 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering medications at 12 months, with 81% completely medication-free. The treatment demonstrated excellent tolerability, with 98% continuing after 12 months, and a favorable safety profile. Glaukos is preparing for an NDA submission to the FDA, with a decision expected by the end of 2023.

Glaukos Corporation (NYSE: GKOS) has announced a major milestone with over one million implantations of its iStent technology worldwide. This achievement underscores Glaukos' pioneering role in Micro-Invasive Glaucoma Surgery (MIGS), reflecting more than 20 years of innovation and investment in glaucoma treatment options.

Industry experts emphasize that iStent has significantly improved patient outcomes and allowed for earlier interventions in glaucoma treatment. Glaukos continues to invest over 30% of its revenue into research and development to enhance its product offerings.

On August 24, iVeena Delivery Systems entered a strategic licensing agreement with Glaukos Corporation (GKOS) for IVMED-80, an eye drop designated for keratoconus. Glaukos paid $10 million upfront and will cover all development costs. The deal includes potential milestone payments and royalties for iVeena. iVeena is also working on IVMED-85, aimed at pediatric myopia, with plans for a clinical trial in early 2023.

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, has announced its management will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 3:45 p.m. ET in Boston, MA. This event will highlight Glaukos' focus on novel therapies for treating glaucoma, corneal disorders, and retinal diseases. A live webcast will be available in the Investors section of the Glaukos website.

iVeena Delivery Systems has entered a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) for exclusive global rights to IVMED-80, a treatment for keratoconus, a rare corneal disorder. IVMED-80 is a proprietary topical eye drop that has shown promising results in a phase 1/2a clinical study, achieving a significant reduction in corneal curvature. Glaukos paid $10 million upfront for the license and will cover all development costs, with further milestone payments and royalties possible. This partnership aims to enhance treatment options for keratoconus patients.

Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iStent infinite Trabecular Micro-Bypass System, the first micro-invasive implantable device approved for standalone glaucoma treatment. This innovative device features a three-stent system designed to lower intraocular pressure (IOP) by restoring natural fluid outflow. CEO Thomas Burns highlighted the device's potential, backed by compelling clinical data. Initial commercial launch activities for iStent infinite are planned for later this year.

Glaukos Corporation (NYSE: GKOS) reported Q2 2022 net sales of $72.7 million, a decrease from $78.1 million in Q2 2021. Key segments included $56.1 million from glaucoma and $16.6 million from corneal health. Gross margin was approximately 75%, down from 77% year-over-year. Notably, R&D expenses surged 31% to $31.7 million. Glaukos raised its full-year revenue guidance to $275 million to $280 million, up from $270 million to $275 million. The company ended the quarter with approximately $400 million in cash and equivalents.